Now available: The AmoyDx® Myeloid Blood Cancer Panel
The AmoyDx® Myeloid Blood Cancer Panel enables a comprehensive molecular genetic analysis for the qualitative detection of SNVs, InDels and fusions in 55 genes associated with myeloid leukemia on DNA and RNA.
The AmoyDx® Myeloid Blood Cancer Panel is a Next-Generation Sequencing-based assay for the detection of mutations (SNVs), insertions and deletions (InDels) as well as fusions in 55 genes on DNA and RNA from bone marrow aspirates. In total, 252 different gene fusions can be detected using this assay.
The focus of this assay is on the tumor entities AML and CML, but may be further suited to characterize other hematologic malignancies. The analysis of the sequence data can be performed locally using the AmoyDx® NGS Data Analysis System (ANDAS).
Please find a detailed description of the AmoyDx® Myeloid Blood Cancer Panel here
This product is for research use only (RUO)
Further topics
Product update: BRCA1 and BRCA2
The new AmoyDx® BRCA Pro Panel is an improved version of the AmoyDx® BRCA1 and BRCA2 Gene Mutation Detection Kit. Both kits enable analysis of the entire coding regions of the BRCA1 and BRCA2 genes, and of exon/ intron boundries in DNA from FFPE specimen and from peripheral whole blood.
IVDR Update October 2022
As a manufacturer and distributor of in vitro diagnostics, our enterprise group with the companies Zytomed Systems GmbH and ZytoVision GmbH attaches great importance to the timely implementation of the requirements of the IVDR (Regulation (EU) 2017/746 of the European Parliament and of the Council of April 5th 2017 on in vitro diagnostic medical devices).
